Hollis-Eden Releases Data from NEUMUNE Study Indicating Survival Benefit against High-Dose Radiation Exposure BussinessWire

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today released data from a pilot study indicating that non-human primates treated with NEUMUNE(TM)(HE2100) after exposure to a high dose of radiation experienced an improved rate of survival over animals receiving placebo or no treatment. NEUMUNE is an investigational immune regulating hormone being developed by Hollis-Eden as a treatment for acute radiation injury pursuant to the U.S. Food and Drug Administration (FDA) “animal rule” for countermeasures to weapons of mass destruction. The Company is presenting the data this week at the 46th Annual Meeting of The American Society for Therapeutic Radiology and Oncology (ASTRO) in Atlanta, Georgia, October 3-7, 2004.